clinical trial · NCT05853367
Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)
Merck Sharp & Dohme LLC·phase1·active not recruiting·n = 95
Metastatic Solid TumorsAdvanced Solid TumorsMK-0472PembrolizumabMK-1084
brief summary
The purpose of this study is to assess the efficacy, safety, and tolerability of MK-0472 administered as monotherapy and in combination with pembrolizumab (MK-3475) or MK-1084 in participants with histologically or cytologically confirmed diagnosis of advanced/metastatic solid tumors.
started
Jul 6, 2023
primary completion
May 26, 2028
completion
May 26, 2028
last updated
Jul 15, 2026
official title
A Phase 1/1b Open-label, Multicenter Clinical Study of MK-0472 as Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol